Author

Bas Oldenburg

METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN TARGET COLONIC MUCOSA, AND WHITE BLOOD CELLS COMPARED TO NON-TARGET RED BLOOD CELLS OF PATIENTS WITH CROHN’S DISEASE
METHOTREXATE POLYGLUTAMATE CONCENTRATIONS IN TARGET COLONIC MUCOSA, AND WHITE BLOOD CELLS COMPARED TO NON-TARGET RED BLOOD CELLS OF PATIENTS WITH CROHN’S DISEASE

Bas Oldenburg  et al.

A HIGHER RED BLOOD CELL METHOTREXATE POLYGLUTAMATE 3 CONCENTRATION IS ASSOCIATED WITH METHOTREXATE DRUG-SURVIVAL IN PATIENTS WITH CROHN’S DISEASE
A HIGHER RED BLOOD CELL METHOTREXATE POLYGLUTAMATE 3 CONCENTRATION IS ASSOCIATED WITH METHOTREXATE DRUG-SURVIVAL IN PATIENTS WITH CROHN’S DISEASE

Bas Oldenburg  et al.

EXPRESSION PROFILING OF WNT PATHWAY GENES IN COLON BIOPSIES OF PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE
EXPRESSION PROFILING OF WNT PATHWAY GENES IN COLON BIOPSIES OF PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE

Bas Oldenburg  et al.

CONTINUATION OF ANTI-TNF IN PATIENTS WITH ULCERATIVE COLITIS IN REMISSION IS NOT COST-EFFECTIVE COMPARED TO TREATMENT WITHDRAWAL: A MARKOV MODEL
CONTINUATION OF ANTI-TNF IN PATIENTS WITH ULCERATIVE COLITIS IN REMISSION IS NOT COST-EFFECTIVE COMPARED TO TREATMENT WITHDRAWAL: A MARKOV MODEL

Bas Oldenburg  et al.

THE GUT MICROBIOME OF HEALTHY SIBLINGS OF INFLAMMATORY BOWEL DISEASE (IBD) TWINS DISPLAYS IBD SIGNATURES
THE GUT MICROBIOME OF HEALTHY SIBLINGS OF INFLAMMATORY BOWEL DISEASE (IBD) TWINS DISPLAYS IBD SIGNATURES

Bas Oldenburg  et al.

COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL
COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

Bas Oldenburg  et al.

SMOKING AND COLITIS-ASSOCIATED COLORECTAL NEOPLASIA: EXPLORING THE RELATIONSHIP
SMOKING AND COLITIS-ASSOCIATED COLORECTAL NEOPLASIA: EXPLORING THE RELATIONSHIP

Bas Oldenburg  et al.

RISK ASSESSMENT FOR POSTOPERATIVE RECURRENCE AFTER ILEOCOLONIC RESECTION IN CROHN'S DISEASE (ON BEHALF OF THE DUTCH INITIATIVE ON CROHN AND COLITIS (ICC)
RISK ASSESSMENT FOR POSTOPERATIVE RECURRENCE AFTER ILEOCOLONIC RESECTION IN CROHN'S DISEASE (ON BEHALF OF THE DUTCH INITIATIVE ON CROHN AND COLITIS (ICC)

Bas Oldenburg  et al.

CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL
CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL

Bas Oldenburg  et al.

WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY
WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY

Bas Oldenburg  et al.

Item 1 - 10 / 10
1